Last reviewed · How we verify
Citalopram and Pindolol
At a glance
| Generic name | Citalopram and Pindolol |
|---|---|
| Also known as | Seropram, Hexapindol® |
| Sponsor | Gitte Moos Knudsen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors (NA)
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citalopram and Pindolol CI brief — competitive landscape report
- Citalopram and Pindolol updates RSS · CI watch RSS
- Gitte Moos Knudsen portfolio CI